Diabetes Unit and Diabetes Foot Unit, San Jacopo Hospital, Pistoia, Italy.
Department of Clinical and Experimental Medicine, School of Human Health Sciences, Florence, Italy.
J Diabetes Res. 2018 Feb 20;2018:1081792. doi: 10.1155/2018/1081792. eCollection 2018.
This study has been performed in diabetic type 2 patients with pain due to peripheral artery disease (PAD) in order to evaluate the efficacy and tolerability of tapentadol prolonged release (PR). . 25 patients with type 2 diabetes (13 F and 12 M) were admitted in the study. The evaluation of the analgesic efficacy of tapentadol PR was based on both the assessment of the intensity of the pain (NRS scale from 0 to 10) and the nature of the pain (DN4 questionnaire) and on assessment of the patient's quality of life and state of health (SF-12 Health Survey). Study duration was 3 months: a baseline visit and follow-up included visits after 1 week, 1 month, 2 months, and 3 months. . At the beginning of the study, the mean intensity of the pain was 7.88 ± 1.17 on the NRS scale and at visit 2 it reduced in a statistically significant way; at the end of the treatment with tapentadol PR, the mean intensity was 2.84 points on the NRS scale. . In type 2 diabetic patients with chronic severe pain due to PAD, tapentadol PR reduced pain intensity, improving the quality of life.
本研究旨在评估盐酸他喷他多缓释片（tapentadol prolonged release，PR）治疗 2 型糖尿病伴外周动脉疾病（peripheral artery disease，PAD）相关慢性疼痛患者的疗效和耐受性。共纳入 25 例 2 型糖尿病患者（13 例女性，12 例男性）。采用数字评分量表（numerical rating scale，NRS）和疼痛性质问卷（DN4）评估盐酸他喷他多 PR 的镇痛疗效，同时评估患者的生活质量和健康状况（SF-12 健康调查）。研究持续 3 个月，包括基线访视和 1 周、1 个月、2 个月和 3 个月的随访。研究开始时，NRS 评分的平均疼痛强度为 7.88±1.17，第 2 次访视时疼痛强度显著降低；治疗结束时，NRS 评分的平均疼痛强度为 2.84 分。盐酸他喷他多 PR 可降低 2 型糖尿病伴慢性严重 PAD 相关疼痛患者的疼痛强度，改善生活质量。
